Adjuvant Pembrolizumab Is Not Associated With Reduced Quality of Life in Resected Stage III Melanoma
Source: Cancer Therapy Advisor, May 2021
Pembrolizumab does not result in a clinically significant decrease in health-related quality of life (HRQOL) compared with placebo when it is administered as adjuvant therapy in patients with resected, high-risk stage III melanoma, according to a study published in The Lancet Oncology.